ATR depletion has been implicated as a tumor targeting strategy in prior reports. In this study published by Thomas et al, the addition of a M6620 has shown an improvement in responsiveness to topotecan in a small phase I clinical trial. 21 patients with various different solid malignancies were enrolled in this study. The ATR-CHK2 pathway has been well implicated in promoting cancer cell survival. This is the first report of the combination of an ATR inhibitor in combination with a topoisomerase inhibitor. 2 patients had a partial response and 7 patients had stable disease of greater than 3 months duration. 1 grade 4 toxicity was seen.
In this phase 2 study published in JCO, researchers added everolimus to fulvestrant in female patients with stage IV breast CA, ER+ Her2 negative, that had progressed on an aromatase inhibitor. There was a 20% improvement in the clinical benefit rate as well as an improvement of 5 months in the median progression free survival.
In this article that was just released in the New England Journal of Medicine, Dr. Jemal and his research team, report on the findings of lung cancer incidence with regards to gender and age demographics. Nationwide population-based incidence of lung cancer with regards to sex, race or ethnic group were evaluated. Patient were broken up into 5 year age increments. Diagnoses were also broken up into 5 year increments starting from 1990 until 2014. Over the past 2 decades, age specific incidence of lung cancer has decreased in both women and men age 30-54 years of age. The declines in men have been much steeper. The team concluded that the patterns of historically higher incidence rate of lung cancer among women have reversed among non- Hispanic whites Hispanics born in the 1960s. These findings are not fully explained by sex differences and smoking behavior.
A research effort led by Dr Lee, published in JTO this month showed that the depth of early response (6 and 12 weeks ) to EGFR targeting oral therapies such as erlotinib did not predict for progression free survival. 1,081 patients cases were reviewed from 5 clinical trials. The authors concluded that early tumor shrinkage did not predict for a progression free survival advantage.
News From PSMG
The latest news at Pacific Shores Medical Group
Disclaimer: This site is not designed to and does not provide medical advice, professional diagnosis, opinion, treatment or services to you or to any other individual. Through this site and linkages to other sites, Pacific Shores Medical Group provides general information for educational purposes only. The information provided in this site, or through linkages to other sites, is not a substitute for medical or professional care, and you should not use the information in place of a visit, call consultation or the advice of your physician or other healthcare provider. Pacific Shores Medical Group is not liable or responsible for any advice, course of treatment, diagnosis or any other information, services or product you obtain through this site.